Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

References

• World Health OrganizationHepatitis C. Fact sheet 1642013 Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.htmlAccessed January 17, 2014
   Google Scholar
• SagnelliEStroffoliniTMeleAThe importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 casesJ Med Virol200575452252715714480
   PubMed Web of Science ®Google Scholar
• PetruzzielloACoppolaNDiodatoAMAge and gender distribution of hepatitis C virus genotypes in the metropolitan area of NaplesIntervirology201356320621223594735
   PubMed Web of Science ®Google Scholar
• GuadagninoVStroffoliniTRapicettaMPrevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern ItalyHepatology1997264100610119328327
   PubMed Web of Science ®Google Scholar
• MaasoumyBWedemeyerHNatural history of acute and chronic hepatitis CBest Pract Res Clin Gastroenterol201226440141223199500
   PubMed Web of Science ®Google Scholar
• FilippiniPCoppolaNScolasticoCDoes HIV infection favor the sexual transmission of hepatitis C?Sex Transm Dis2001281272572911725228
   PubMed Web of Science ®Google Scholar
• GentileIDe StefanoADi FlumeriGConcomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case reportIn Vivo201327452752923812225
   PubMed Web of Science ®Google Scholar
• GentileIDi FlumeriGScaricaSAcute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapyMinerva Urol Nefrol2013651838423538314
   PubMed Web of Science ®Google Scholar
• MeleASpadaESaglioccaLRisk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in ItalyJ Hepatol200135228428911580153
   PubMed Web of Science ®Google Scholar
• CarneyKDhallaSAytamanATennerCTFrancoisFAssociation of tattooing and hepatitis C virus infection: a multicenter case-control studyHepatology20135762117212323315899
   PubMed Web of Science ®Google Scholar
• CoppolaNPisapiaRTonzielloGImprovement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity IndexJ Clin Virol200946322222919758839
   PubMed Web of Science ®Google Scholar
• CoppolaNPisapiaRMarroccoCAnti-HCV IgG avidity index in acute hepatitis CJ Clin Virol200740211011517720621
   PubMed Web of Science ®Google Scholar
• GentileICoppolaNPasqualeGA simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis CHepat Mon2013135e835223967022
   PubMed Web of Science ®Google Scholar
• HoofnagleJHHepatitis C: the clinical spectrum of diseaseHepatology1997263 Suppl 115S20S9305658
   PubMed Web of Science ®Google Scholar
• FortunatoGCastaldoGOrianiGMultivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitisClin Chem20014791696170011514405
   PubMed Web of Science ®Google Scholar
• FortunatoGCalcagnoGBresciamorraVMultiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genesJ Interferon Cytokine Res200828314115218338947
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARZappuloEBorgiaGIs it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?Infez Med2014221111824651085
   PubMedGoogle Scholar
• GentileIMeolaMBuonomoARHuman platelet antigen-3 genotype predicts platelet count in patients with HCV infectionIn Vivo201327677377724292581
   PubMed Web of Science ®Google Scholar
• SagnelliEPisaturoMStanzioneMPresentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis CClin Gastroenterol Hepatol201313130046600467
   Google Scholar
• CoppolaNGentileIPasqualeGAnti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis CAnn Hepatol2014131202624378262
   PubMed Web of Science ®Google Scholar
• GentileIViolaCGrafMA simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitisJ Clin Gastroenterol2009431818718562980
   PubMed Web of Science ®Google Scholar
• SagnelliCUberti-FoppaCPasqualeGFactors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfectionInfection201341595996723839212
   PubMed Web of Science ®Google Scholar
• FerrariSMFallahiPMancusiCHCV-related autoimmune disorders in HCV chronic infectionClin Ter20131644e305e31224045529
   PubMed Web of Science ®Google Scholar
• CoppolaNPisaturoMGuastafierroSIncreased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapyDig Liver Dis2012441495421885355
   PubMedGoogle Scholar
• ZampinoRCoppolaNCirilloGAbdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis CJ Viral Hep2013208517523
   PubMed Web of Science ®Google Scholar
• CoppolaNPascalisSDPisaturoMSustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV RNA clearance in peripheral blood mononuclear cellsJ Clin Virol201358474875024140030
   PubMed Web of Science ®Google Scholar
• FuscoFD’AnzeoGRossiAErectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literatureExpert Opin Pharmacother201314182533254424215104
   PubMed Web of Science ®Google Scholar
• BraksREGanne-CarrieNFontaineHEffect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirinWorld J Gastroenterol200713425648565317948941
   PubMed Web of Science ®Google Scholar
• BrunoSStroffoliniTColomboMSustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective studyHepatology200745357958717326216
   PubMed Web of Science ®Google Scholar
• Di MarcoVAlmasioPLFerraroDPeg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trialJ Hepatol200747448449117692985
   PubMed Web of Science ®Google Scholar
• GentileIBorgiaGSurrogate endpoints and non-inferiority trials in chronic viral hepatitisJ Hepatol201052577820347500
   PubMed Web of Science ®Google Scholar
• AuJSPockrosPJNovel therapeutic approaches for hepatitis CClin Pharmacol Ther2014951788824126682
   PubMed Web of Science ®Google Scholar
• JaroszewiczJFlisiakRDusheikoGA pill for HCV – myth or foreseeable future?Liver Int201434161123998627
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationApproval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C2013 Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htmAccessed January 17, 2014
   Google Scholar
• GentileIBorgiaFBuonomoARCastaldoGBorgiaGA novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvirCurr Med Chem201320303733374223848533
   PubMed Web of Science ®Google Scholar
• GentileIBorgiaFZappuloEBuonomoARSperaAMCastaldoGEfficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: The Dawn of a New EraRev Recent Clin Trials20149117
   PubMedGoogle Scholar
• GentileIViolaCBorgiaFCastaldoGBorgiaGTelaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infectionCurr Med Chem20091691115112119275615
   PubMed Web of Science ®Google Scholar
• MederackeIWedemeyerHMannsMPBoceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infectionCurr Opin Investig Drugs2009102181189
   PubMedGoogle Scholar
• YouDMPockrosPJSimeprevir for the treatment of chronic hepatitis CExpert Opin Pharmacother201314182581258924138198
   PubMed Web of Science ®Google Scholar
• CoppolaNPisaturoMTonzielloGSagnelliCSagnelliEAngelilloIFEfficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysisBMC Infect Dis20121235714712334
   Google Scholar
• GhanyMGStraderDBThomasDLSeeffLBDiagnosis, management, and treatment of hepatitis C: an updateHepatology20094941335137419330875
   PubMed Web of Science ®Google Scholar
• MoriscoFGranataRStroffoliniTSustained virological response: a milestone in the treatment of chronic hepatitis CWorld J Gastroenterol201319182793279823687416
   PubMed Web of Science ®Google Scholar
• GhanyMGNelsonDRStraderDBThomasDLSeeffLBAn update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology20115441433144421898493
   PubMed Web of Science ®Google Scholar
• PoordadFAgarwalKYounesZCohenDEXieWPodsadeckiTLow relapse rate leads to high concordance of SVR4 and SVR12 with SVR24 after treatment with ABT-450/r, ABT-267, ABT-333 + ribavirin in patients with chronic HCV genotype 1 infection in the AVIATOR studyPaper presented at the 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1–5, 2013Washington, DC, USA
   Google Scholar
• PoordadFMcConeJJrBaconBRBoceprevir for untreated chronic HCV genotype 1 infectionN Engl J Med2011364131195120621449783
   PubMed Web of Science ®Google Scholar
• JacobsonIMMcHutchisonJGDusheikoGTelaprevir for previously untreated chronic hepatitis C virus infectionN Engl J Med2011364252405241621696307
   PubMed Web of Science ®Google Scholar
• LangeCMBojungaJRamos-LopezEVitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapyJ Hepatol201154588789321145801
   PubMed Web of Science ®Google Scholar
• IsmailMHPrediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infectionJ Family Community Med2013201354023723729
   PubMedGoogle Scholar
• BorgiaGGentileIFortunatoGHomocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: a prospective studyLiver Int200929224825218662278
   PubMed Web of Science ®Google Scholar
• DistanteSBjoroKHellumKBRaised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infectionLiver200222326927512100578
   PubMedGoogle Scholar
• GentileIViolaCPaesanoLIron depletion before HCV antiviral therapy: a pilot, randomized, controlled trialJ Clin Apher200924519019619760753
   PubMed Web of Science ®Google Scholar
• Abu-MouchSFiremanZJarchovskyJZeinaARAssyNVitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patientsWorld J Gastroenterol201117475184519022215943
   PubMed Web of Science ®Google Scholar
• NimerAMouchAVitamin D improves viral response in hepatitis C genotype 2–3 naive patientsWorld J Gastroenterol201218880080522371640
   PubMed Web of Science ®Google Scholar
• CoppolaNMarroneAPisaturoMRole of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infectionEur J Clin Microbiol Infect Dis201433455956724081499
   PubMed Web of Science ®Google Scholar
• CoppolaNPisaturoMSagnelliCSagnelliEAngelilloIFPeg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsPLoS One201494e9454224728219
   PubMed Web of Science ®Google Scholar
• GentileIBorgiaFCoppolaNBuonomoARCastaldoGBorgiaGDaclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5ACurr Med Chem201421121391140424372205
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARBorgiaFCastaldoGBorgiaGLedipasvir: a novel synthetic antiviral for the treatment of HCV infectionExpert Opin Investig Drugs2014234561571
   PubMed Web of Science ®Google Scholar
• AsselahTABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infectionJ Hepatol201359488588823707374
   PubMed Web of Science ®Google Scholar
• StedmanCACurrent prospects for interferon-free treatment of hepatitis C in 2012J Gastroenterol Hepatol2013281384523137126
   PubMed Web of Science ®Google Scholar
• SarrazinCHezodeCZeuzemSPawlotskyJMAntiviral strategies in hepatitis C virus infectionJ Hepatol2012561S88S10022300469
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARBorgiaFZappuloECastaldoGBorgiaGMK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infectionExpert Opin Investig Drugs2014235719728
   PubMed Web of Science ®Google Scholar
• GentileICoppolaNBuonomoARZappuloEBorgiaGInvestigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virusExpert Opin Investig Drugs2014113
   Web of Science ®Google Scholar
• GentileIBuonomoARZappuloEBorgiaGInterferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?Expert Rev Anti Infect Ther201412776377324918116
   PubMed Web of Science ®Google Scholar
• GentileICarleoMABorgiaFCastaldoGBorgiaGThe efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virusExpert Opin Investig Drugs2010191151159
   PubMed Web of Science ®Google Scholar
• YanYLiYMunshiSComplex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal formProtein Sci1998748378479568891
   PubMed Web of Science ®Google Scholar
• GermainMAChatel-ChaixLGagneBElucidating novel hepatitis C virus/host interactions using combined mass spectrometry and functional genomics approachesMol Cell Proteomics201413118420324169621
   PubMed Web of Science ®Google Scholar
• McPheeFSheafferAKFriborgJPreclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)Antimicrob Agents Chemother201256105387539622869577
   PubMed Web of Science ®Google Scholar
• FriborgJLevineSChenCCombinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replicationAntimicrob Agents Chemother20135731312132223274666
   PubMed Web of Science ®Google Scholar
• PasquinelliCEleyTVillegasCSafety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infectionHepatology2009504411A412A
   Web of Science ®Google Scholar
• EleyTHeBChangIThe effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitorAntivir Ther472014 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• GarimellaTHeBLuoW-LAsunaprevir pharmacokinetics and safety in subjects with impaired renal functionHepatology201358430A
   Web of Science ®Google Scholar
• GarimellaTAdamczykRHuPNo clinically relevant interactions between asunaprevir and selective serotonin reuptake inhibitors (escitalopram and sertraline) in healthy subjectsHepatology201358445A446A
   Web of Science ®Google Scholar
• PasquinelliCMcPheeFEleyTSingle- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis CAntimicrob Agents Chemother20125641838184422290978
   PubMed Web of Science ®Google Scholar
• BronowickiJPPolSThuluvathPJRandomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis CAntivir Ther201318788589323804631
   PubMed Web of Science ®Google Scholar
• BronowickiJPRatziuVGadanoAAsunaprevir with Peginterferon-alfa and ribavirin in treatment-naive patients with genotype-1 or-4 chronic hepatitis C: SVR24 results from a randomized phase 2b study (AI447016)J Hepatol201358S571S572
   Web of Science ®Google Scholar
• VierlingJMLatailladeMGaneEJSustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE studyHepatology201256615221523
   Web of Science ®Google Scholar
• LokASGardinerDFLawitzEPreliminary study of two antiviral agents for hepatitis C genotype 1N Engl J Med2012366321622422256805
   PubMed Web of Science ®Google Scholar
• LokASGardinerDFHezodeCRandomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null respondersJ Hepatol201460349049924444658
   PubMed Web of Science ®Google Scholar
• SuzukiYIkedaKSuzukiFDual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment optionsJ Hepatol201358465566223183526
   PubMed Web of Science ®Google Scholar
• KumadaHSuzukiYIkedaKDaclatasvir plus asunaprevir for chronic HCV genotype 1b infectionHepatology20145962083209124604476
   PubMed Web of Science ®Google Scholar
• MannsMPolSJacobsonIAll-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1B infection: phase 3 study resultsJ Hepatol2014601S524S525
   Google Scholar
• EversonGTSimsKDRodriguez-TorresMEfficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGastroenterology2014146242042924184132
   PubMed Web of Science ®Google Scholar
• EversonGTSimsKDThuluvathPJPhase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infectionHepatology20135861377A
   Web of Science ®Google Scholar
• McPheeFFriborgJLevineSResistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevirAntimicrob Agents Chemother20125673670368122508297
   PubMed Web of Science ®Google Scholar
• McPheeFHernandezDYuFResistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevirHepatology201358390291123504694
   PubMed Web of Science ®Google Scholar
• KarinoYToyotaJIkedaKCharacterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevirJ Hepatol201358464665423178977
   PubMed Web of Science ®Google Scholar
• McPheeFToyotaJChayamaKAnalysis of HCV resistance variants in a Phase 3 trial of daclatasvir combined with asunaprevir for Japanese patients with genotype 1b infectionHepatology201358749A
   Web of Science ®Google Scholar
• BorgiaGReynaudLGentileIPernicious anemia during IFN-alpha treatment for chronic hepatitis CJ Interferon Cytokine Res2003231111212639294
   PubMed Web of Science ®Google Scholar
• BorgiaGReynaudLGentileIMyasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis CJ Interferon Cytokine Res200121746947011506739
   PubMed Web of Science ®Google Scholar
• GentileIViolaCReynaudLHemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culpritJ Interferon Cytokine Res200525528328515871666
   PubMed Web of Science ®Google Scholar
• TosoneGBorgiaGGentileIA case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?Acta Diabetol200744316716917721757
   PubMed Web of Science ®Google Scholar
• HezodeCFontaineHDorivalCTriple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890J Hepatol201359343444123669289
   PubMed Web of Science ®Google Scholar
• D’AmbrosioRColomboMSafety of direct antiviral agents in real lifeDig Liver Dis201345Suppl 5S363S36624091117
   PubMedGoogle Scholar
• BorgiaGGentileITreating chronic hepatitis B: today and tomorrowCurr Med Chem200613232839285517073632
   PubMed Web of Science ®Google Scholar
• BorgiaGCarleoMAGaetaGBGentileIHepatitis B in pregnancyWorld J Gastroenterol201218344677468323002336
   PubMed Web of Science ®Google Scholar
• GentileIZappuloEBuonomoARBorgiaGPrevention of mother-to-child transmission of HBV and HCVExpert Rev Anti Infect Ther5202014 [Epub ahead of print.]
   Web of Science ®Google Scholar